Atossa Therapeutics (ATOS) announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,479,790 B2, titled, “Methods for Making and Using Endoxifen.” The newly issued patent includes 100 claims directed to enteric oral formulations of highly pure (Z)-endoxifen free base, as well as methods of using those compositions to treat a range of hormone-dependent breast disorders and other estrogen-related conditions. The patent also covers specific solid oral dosage forms and stable formulations providing therapeutically meaningful and sustained systemic exposure to (Z)-endoxifen.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Strategic Advancements and Regulatory Progress Boost Atossa Therapeutics’ Outlook
- Atossa Completes FDA Meeting on Regulatory Strategies
- Atossa Therapeutics details accelerated FDA strategy to advance (Z)-endoxifen
- Atossa Therapeutics, Insilico Medicine publish study of (Z)-endoxifen in GBM
- Atossa Therapeutics: Strategic Advancements in Breast Cancer Treatment Drive Buy Rating